Halocarbon appoints David Bacon as Chief Executive

His top priorities will be leading the next phase of the company’s growth and product innovation

Halocarbon Products, a worldwide producer of speciality fluorochemicals and inhalation anaesthetics, has announced that David Bacon will be joining the company as Chief Executive on 28 April.

Bacon comes to Halocarbon with more than 24 years of experience in market analysis and driving innovation. As CEO of Halocarbon, Bacon’s top priorities will be leading the next phase of the company’s growth and product innovation.

Most recently, Bacon was President of LSP Products Group. Prior to this he was General Manager for the AT Plastics business at Celanese. He has also worked as a management consultant for McKinsey & Company.

Bacon began his professional career at Exxon, where held roles of increasing responsibility in process and refinery engineering.

You may also like

Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Ingredients

Rousselot and IamFluidics launch dissolvable microcarrier for cell culturing

The alginate and denatured collagen based product allows researchers to produce scalable cell cultures for biologic drugs and cell therapies
Ingredients

Therapeutic: vimseltinib for tenosynovial giant cell tumour

Tenosynovial giant cell tumour (TGCT) is a rare, non-malignant tumour that results from a translocation in the colony stimulating factor 1 (CSF1) gene
Ingredients

Therapeutic: brensocatib for bronchiectasis

The chronic lung disease bronchiectasis is a serious condition in which the bronchi become permanently dilated because of a cycle of infection, inflammation and damage to the lung tissue
Ingredients

Logical Biological expands its raw pharma material development and supply capabilities with new lab

The raw material supplier can now better serve in vitro diagnostic (IVD) manufacturers, as it has a significantly larger operational capacity
Ingredients

Biosynth inaugurates its Biological Technology site in Suzhou, China

The new site will serve the Chinese domestic market, providing raw materials for vaccines and pharmaceuticals, while dealing regional distribution and handling
Manufacturing

New small-scale In-Line mixer range from Silverson Machines

Silverson launches versatile small-scale mixers for pharma and biotech applications
Subscribe now